IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity.
Two mouse IFN-gamma receptor (MoIFN gamma R)-Ig fusion proteins, which were constructed for the purpose of creating new efficient mouse IFN-gamma (MoIFN-gamma) inhibitor molecules, were studied in vivo to determine their plasma half-life and immunogenicity, and to show their biologic activity. The hybrid proteins show 40-h blood persistency. They do not provoke an antibody response when injected into mice, and they are biologically active in vivo, as demonstrated by the prevention of streptozotocin-induced diabetes. The two fusion proteins are efficient MoIFN-gamma antagonists and can be used in mouse models of human diseases to investigate the role of MoIFN gamma in these pathologic states.
Kürschner
C
C
Department of Biology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Ozmen
L
L
Garotta
G
G
Dembic
Z
Z
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000517:prevention & control; D004195:Disease Models, Animal; D006207:Half-Life; D006386:Hemagglutination Tests; D007074:Immunoglobulin G / Q000276:immunology*; D007371:Interferon-gamma / Q000037:antagonists & inhibitors*; D051379:Mice; D008810:Mice, Inbred C57BL; D011863:Radioimmunoassay; D017471:Receptors, Interferon / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D000096743:Interferon gamma Receptor
D001786:Blood Glucose; D007074:Immunoglobulin G; D007371:Interferon-gamma; D017471:Receptors, Interferon; D011993:Recombinant Fusion Proteins; D000096743:Interferon gamma Receptor